FBR & Co reissued their outperform rating on shares of Prima BioMed Ltd. (NASDAQ:PBMD) in a report issued on Friday. The firm currently has a $6.00 price target on the stock.
Immutep Ltd. buy Quitte
Start price
21.07.16
/
50%
€0.15
Target price
23.01.17
€0.20
Performance (%)
-13.33%
End price
23.01.17
€0.13
Summary
This prediction ended on 23.01.17 with a price of €0.13. The price of Immutep Ltd. has decreased during the runtime of the prediction. Compared to the start price this resulted in a performance of -13.33%. Quitte has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Immutep Ltd. | -10.938% | -10.938% | 14.573% | 30.884% |
| iShares Core DAX® | -0.436% | 1.181% | 14.210% | 57.331% |
| iShares Nasdaq 100 | 0.854% | 1.475% | 5.797% | 88.129% |
| iShares Nikkei 225® | 2.652% | 6.401% | 19.133% | 49.690% |
| iShares S&P 500 | 1.190% | 1.169% | 2.686% | 59.994% |
Comments by Quitte for this prediction
In the thread Immutep Ltd. diskutieren
wer wagt ....
(Laufzeit überschritten)